Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma.

Trial Profile

An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Atezolizumab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary)
  • Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 16 Aug 2018 According to an Inovio Pharmaceuticals media release, first patient has been dosed in the trial. The company expects to produce interim clinical results in 2019.
    • 20 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 16 Oct 2017 Status changed from planning to recruiting, according to an Inovio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top